Page 3 - Head Of Global Product Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Roche s Phase I Trial Of CT-388 To Treat Obesity And Type 2 Diabetes Report Positive Results

Swiss drug major Roche (RHHBY) announced Thursday positive results from the Phase I clinical trial of its dual GLP-1/GIP receptor agonist CT-388 being developed for the treatment of obesity and type 2 diabetes.

Levi garrawayMore such health newsHead of global product developmentChief medical officerGlobal product development

Roche: positive CHMP opinion for Alecensa

Roche announced today that the European Medicines Agency s Committee for Medicinal Products for Human Use has recommended approval of Alecensa as monotherapy, as adjuvant therapy in patients with.

Levi garrawayHead of global product developmentEuropean medicines agencyMedicinal productsHuman useChief medical officerGlobal product

FDA approves Roche s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer Seite 1

19.04.2024 - Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an . Seite 1

Levi garrawayKen culverDrug administrationHead of global product developmentClinical affairsThenational comprehensive cancer networkNational comprehensive cancer networkChief medical officerGlobal productRoche holding aktie

F Hoffmann-La Roche Ltd: FDA approves Roche s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

F Hoffmann-La Roche Ltd: FDA approves Roche s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesLoren kalmSabine borngrDennis riedlBruno eschliNathalie altermattRebekka schnellBirgit masjostSimon goldsboroughKirti pandeySileia urechLevi garrawayKarsten kleineKen culverHead of global product developmentKamakura research laboratories

FDA approves Roche s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung.

United statesLevi garrawayRebekka schnellKarsten kleineSimon goldsboroughSileia urechNathalie altermattBruno eschliKirti pandeyKen culverLoren kalmSabine borngrBirgit masjostFrench cooperative thoracic intergroupClinical affairsAmerican cancer society